Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour.

Abstract

In this study, the response of Imitanib Mesylate in patients with Gastro-intestinal stromal cell tumour (GIST) was assessed. GIST results from a mutation in one of the receptor protein tyrosine kinases. Imitanib Mesylate, a tyrosine kinase inhibitor, has emerged as a promising new treatment for GISTs. Total 16 cases were reviewed. Diagnosis was based on… (More)

Topics

Cite this paper

@article{Ladha2008ResponseOI, title={Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour.}, author={Abdullah Ladha and Mohammad Usman Shaikh}, journal={JPMA. The Journal of the Pakistan Medical Association}, year={2008}, volume={58 12}, pages={696-7} }